
|Videos|January 17, 2023
Common Molecular Alterations in Advanced RAI-R-DTC
Author(s)Lori J. Wirth, MD
Dr Lori Wirth details the common molecular alterations seen in patients with advanced RAO-R-DTC and which testing platforms she recommends.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5





















